These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19803560)

  • 1. Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon.
    Fairman KA; Curtiss FR
    J Manag Care Pharm; 2009 Oct; 15(8):696-700. PubMed ID: 19803560
    [No Abstract]   [Full Text] [Related]  

  • 2. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.
    Gerrald KR; Van Scoyoc E; Wines RC; Runge T; Jonas DE
    Diabetes Obes Metab; 2012 Jun; 14(6):481-92. PubMed ID: 22098472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
    Jermendy G
    Orv Hetil; 2011 Sep; 152(37):1471-6. PubMed ID: 21893477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPP-4 inhibitors in clinical practice.
    Palalau AI; Tahrani AA; Piya MK; Barnett AH
    Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 8. Initial therapy for type 2 diabetes. Examination of a combination approach.
    Henson K; Hight R; Welborn D; Wyatt S
    Adv Nurse Pract; 2009 Jun; 17(6):43-4. PubMed ID: 20000183
    [No Abstract]   [Full Text] [Related]  

  • 9. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ
    Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
    Lumb AN; Gallen IW
    Diabet Med; 2009 Feb; 26(2):189-90. PubMed ID: 19236626
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
    Poucher SM; Cheetham S; Francis J; Zinker B; Kirby M; Vickers SP
    Diabetes Obes Metab; 2012 Oct; 14(10):918-26. PubMed ID: 22564773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managed care perspective on three new agents for type 2 diabetes.
    VanDeKoppel S; Choe HM; Sweet BV
    J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
    Fakhoury WK; Lereun C; Wright D
    Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin (Januvia) for type 2 diabetes.
    Med Lett Drugs Ther; 2007 Jan; 49(1251):1-3. PubMed ID: 17179897
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combination antidiabetic therapy. Better control of blood glucose values].
    Bischoff A
    MMW Fortschr Med; 2009 Oct; 151(42):55. PubMed ID: 19938787
    [No Abstract]   [Full Text] [Related]  

  • 16. DPP4 inhibitors: a new approach in diabetes treatment.
    Doupis J; Veves A
    Adv Ther; 2008 Jul; 25(7):627-43. PubMed ID: 18641927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
    Ahrén B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatments for diabetes.
    Bloomgarden ZT; Inzucchi SE
    N Engl J Med; 2007 May; 356(21):2219-20; author reply 2222-3. PubMed ID: 17522409
    [No Abstract]   [Full Text] [Related]  

  • 19. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Campbell RK
    Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].
    Rabasseda X
    Drugs Today (Barc); 2011 Nov; 47 Suppl D():1-8. PubMed ID: 22439134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.